Phosphoprotein enriched in diabetes gene product (Ped/pea-15) is increased in omental adipose tissue of women with the polycystic ovary syndrome: Ex vivo regulation of ped/pea-15 by glucose, insulin and metformin

Diabetes, Obesity and Metabolism

Volumn 13, Issue 2, 2011, Pages 181-184

  Tan, B K ^a   Chen, J ^a   Adya, R ^a   Randeva, H S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Adipose tissue; Antidiabetic drug; Biguanides; Diabetes mellitus; Metformin

Indexed keywords

GENE PRODUCT; GLUCOSE; INSULIN; MESSENGER RNA; METFORMIN; PHOSPHOPROTEIN; PHOSPHOPROTEIN ENRICHED IN DIABETES GENE PRODUCT; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; CONTROLLED STUDY; EX VIVO STUDY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; OMENTUM; OVARY POLYCYSTIC DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUBCUTANEOUS TISSUE; TISSUE LEVEL;

EID: 78650666774     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01329.x     Document Type: Letter

References (12)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
2. Condorelli G, Vigliotta G, Iavarone C et al. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J 1998; 17: 3858-3866.
3. Tan BK, Adya R, Chen J et al. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 2009; 83: 566-574.
4. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010; 87: 407-416.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
6. Valentino R, Lupoli GA, Raciti GA et al. The PEA15 gene is overexpressed and related to insulin resistance in healthy first-degree relatives of patients with type 2 diabetes. Diabetologia 2006; 49: 3058-3066.
7. Savastano S, Orio F Jr. Palomba S et al. Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 67: 557-562.
8. Li J, Peet GW, Balzarano D et al. Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem 2001; 276: 18579-18590.
9. Nardo LG, Rai R. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol 2001; 15: 373-380.
10. Johnson AB, Webster JM, Sum CF et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42: 1217-1222.
11. Perriello G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
12. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.